Patient, 60, is given alpha-radiation to target the tumor without harming healthy tissue in ‘historical’ procedure

CytoReason will profile one of the German multinational science and technology company's leading immuno-oncology drugs.

Oncohost developed a platform to identify key biological processes and proteins that drive response in patients undergoing cancer treatment.

Novellus tailors actionable cancer treatment for patients through the development of a drug that delays the BRAF gene mutation.

Founded in 2017, Nucleai developed a platform that leverages tissue datasets to produce insights into cancer biology, increase clinical trial efficacy and improve patient care.

The company developed breakthrough radiation cancer therapy and is embarking on a number of new of clinical trials.

The company aims to use the funding to advance its immuno-oncology drug candidates, especially its lead product, DSP107.

The Rehovot-based company uses its Selective T cell Redirection (STR) platform to develop targeted anticancer immunotherapies.

To mark World Cancer Day, NoCamels is highlighting some recent findings in research, clinical trials, detection methods, and new therapies - all from so far this year.

Israeli biotech company Accelerated Evolution Biotechnologies says it developed a cure for all cancers; top scientists and researchers issue warnings.

Elephants are masters at fighting off cancer. Now a team of Israeli scientists are using elephant genes to fight cancer in humans.

An Israeli biotechnology company is developing immunotherapy that's designed to prevent cancer from returning.

One of the reasons why chemotherapy treatments are difficult is because cancer cells are equipped with sophisticated defense mechanisms on their membranes that resist contact from anticancer drugs. Scientists at the Technion studied the complexities of this mechanism to develop a novel therapy strategy they calls the "Pharmacological Trojan Horse".

Researchers from various fields at the Weizmann Institute in Israel have joined forces to create a model that can explain "medical mysteries" related to side-effects of chemotherapy. This understanding of the causes of infections can lead to a more individual approach to cancer treatment.

Researchers from the Hebrew University of Jerusalem developed a new method to treat cancer using a protein extracted from the HIV virus. This protein can prevent the restoration of cancerous cells damaged by radiation therapy.